Tome Biosciences

Phase A — Understand the business

Lens 1 · Company Overview

What it was. A Watertown, MA gene-editing platform company (founded 2021, launched publicly Dec 2023) built to commercialize Programmable Genomic Integration (PGI) — the ability to insert any DNA sequence of any size, at any programmed location, without a double-strand break. The flagship tech, PASTE (Programmable Addition via Site-specific Targeting Elements), fuses a prime editor to a serine integrase: prime editing writes a short "landing pad" (attB/attP site) into the genome, then the integrase drops a large cargo into it.

Business model (intended, never reached commercial stage). Classic platform biotech: build one broadly-applicable insertion technology, then spin out a pipeline of in-vivo integrative gene therapies and ex-vivo cell therapies, funded by venture capital and eventually pharma partnerships / an IPO. Zero revenue, zero products, pre-clinical throughout its entire life. The value proposition to investors was "one medicine per gene, irrespective of the patient's specific mutation" — replace the whole gene rather than correct one point mutation, collapsing the "one drug per mutation" economics of base/prime editing.

Customers / suppliers / competitors.

• Customers: none (pre-revenue). End-market would have been patients with monogenic diseases (payers = insurers/health systems) — never reached.
• Suppliers: the core IP was licensed from MIT (McGovern Institute); manufacturing would have relied on CDMOs / LNP + AAV delivery vendors (never scaled).
• Competitors: Prime Medicine (PRME), Tessera Therapeutics (private), Metagenomi (MGX), plus the broader base-/prime-editing cohort — Intellia (NTLA), Beam (BEAM), CRISPR Therapeutics (CRSP), Editas (EDIT), Verve (VERV). On the specific "large-cargo insertion" axis, the direct rivals were Prime Medicine's PASSIGE and Tessera's "Gene Writing."

Contract structure / payment terms. n/a — no commercial contracts. The one material transaction was the Replace Therapeutics acquisition (Jan 2024): $65M upfront/near-term + up to $185M total in stock and cash contingent on milestones.

Lens 2 · Supply Chain (→ CDMO / manufacturing, adapted for +clinical)

For a pre-clinical editor, the "supply chain" is the IP → tool → delivery → manufacturing → clinic stack. Named where sourceable:

• Upstream IP (single most important input): MIT / McGovern Institute — PASTE was invented by Omar Abudayyeh & Jonathan Gootenberg as McGovern Fellows; Tome held an exclusive license to the PASTE estate; US patents issued 2023 (USPTO 11,572,556 / 11,827,881 / 11,834,658 — "site-specific genetic engineering... via programmable addition (PASTE)"). Chokepoint: the whole company sat on top of a single university license + a contested patent position (see Lens 3/10).
• Enzyme/tool inputs: prime-editor components (Cas9-nickase + reverse transcriptase, lineage from David Liu's Broad prime-editing work) + serine integrases (e.g. Bxb1). The prime-editing lineage is precisely where the licensing overhang sits — an open question whether PASTE users also need a prime-editing patent license (Broad/Prime Medicine estate).
• Acquired capability: Replace Therapeutics added ligase-mediated PGI (L-PGI) for small (1–100s bp) edits, complementary to Tome's integrase-mediated I-PGI for large (>1,000 bp) cargo.
• Delivery + manufacturing (never built out): would have needed LNP (in-vivo liver) and viral/iPSC engineering (ex-vivo cell therapy). CTO Matt Barrows led Moderna's COVID-vaccine manufacturing scale-up — the hire signaled manufacturing ambition that never got exercised.

Single-source dependency verdict: the chain was fatally top-heavy — one licensed platform, one contested patent lineage, one funding source (VC), and no revenue to internally fund the multi-year, multi-hundred-million-dollar path to the clinic. When the VC tap closed, the chain had no second leg.

Lens 3 · Competitive Advantages (moats)

The claimed moat: technical differentiation. PASTE/PGI could insert very large cargo — published range 779 bp up to ~36,000 bp, and cited capacity to >30–50 kb — vastly beyond base editing (single bases) or prime editing (short indels). If it worked at therapeutic efficiency and safety, it would be the "fourth and final chapter of genomic medicine" (a16z's framing): whole-gene replacement, mutation-agnostic, no double-strand break (lower genotoxicity than Cas9-cut-and-HDR).

Why the moat proved weak / non-durable (the crux of the whole story):

1. Efficiency, not capability, is the binding constraint — and rivals matched or beat it. David Liu (the prime-editing inventor, 2025 Breakthrough Prize) stated "we have consistently observed PASTE yielding lower integration efficiencies than simple untethered prime editing + recombinase systems". Liu's PASSIGE with an evolved recombinase (eeBxb1) hit ~23% average targeted integration (4.2× wild-type Bxb1), >30% at some sites in primary human fibroblasts. A large-cargo tool nobody can beat on size but that a competitor beats on efficiency has a narrow moat.
2. Fused vs. unfused architecture — contested advantage. Tome fused prime editor + integrase into one protein; Liu argues "we have never observed any benefit from fusing". If the core architectural choice confers no edge, the differentiation collapses toward "same idea, worse execution."
3. IP moat is porous. Tome held PASTE patents but may still need a prime-editing license (Broad/Prime Medicine) — an unresolved overhang, not a clean freedom-to-operate fortress.
4. No scale, brand, switching-cost, or network moat — pre-revenue platform with no installed base.

Bargaining power: effectively none by mid-2024 — a cash-poor pre-clinical company shopping its assets to acquirers has negative bargaining power (fire-sale dynamics). At launch, the pedigree (MIT founders, marquee VCs) gave it temporary fundraising power, which evaporated when the sector re-rated.

Lens 4 · Segments

n/a — single pre-revenue platform, no reportable segments, no segments.csv data (file empty on research layer). The nearest analog to "segments" is the two technology arms and the two lead programs:

• I-PGI (integrase-mediated, large cargo >1 kb) — the flagship.
• L-PGI (ligase-mediated, small edits 1–100s bp) — acquired via Replace.
• Program 1 — in-vivo integrative gene therapy for PKU (phenylketonuria), the declared lead indication.
• Program 2 — ex-vivo CD19/BCMA CAR-iNK cell therapy for renal autoimmune disease.

No revenue, EBITDA, or geographic split exists to break out. ``.

---

Phase B — Measure performance

(No P&L, no earnings, no tape — company is private and defunct. Per the +clinical overlay, Phase B is re-pointed to pipeline, catalysts, and the funding/valuation trajectory; per +private, Lens 5→funding, Lens 7→cap table.)

Lens 5 · Funding & Valuation Trajectory (+private swap) + Pipeline-by-phase (+clinical swap)

Funding history (all ``, unaudited):

Valuation: never publicly disclosed a post-money mark; Series A+B of $213M on a stealth MIT platform implies a launch valuation plausibly in the **~$400M–$800M range **. By mid-2024 the implied equity value was ~zero to salvage (asset-sale dynamics). Burn signal: raised $213M, spent $65M+ on Replace, staffed to ~130–150 FTE, and ran dry in under 12 months — an implied gross burn well north of **$100M+/year **.

Pipeline by phase (+clinical — the asset table IS the company):

The single most important scientific fact: the PKU program produced arguably the best data in the company's life — >10% liver insertion in NHP, a curative-level threshold — yet it still wasn't enough to raise a Series C in the 2024 funding winter. When the layoffs hit, CSO John Finn went into "salvage mode" and had the team write seven preprints in four weeks to preserve the work "so no one had to do this again". That is the epitaph: the science was real; the capital markets were closed.

Lens 6 · Founder/leadership signal (+private — founder interviews, not earnings calls)

No earnings calls exist. Sentiment reads off founder/CEO commentary and its arc:

• Launch (Dec 2023): maximal confidence — Kakkar called PGI a way to "reprogram the human genome with an elegance and efficiency previously unimaginable" and framed PASTE as revolutionary.
• Collapse (Aug 2024): the tone flipped to defensive attribution to the market, not the tech: "despite our clear scientific progress, investor sentiment has shifted dramatically across the gene editing space, particularly for preclinical companies". The recurring word that disappeared between the two dates: any claim of a near-term clinical/IND catalyst that would have justified the burn.
• Independent scientific voice (the tell): the loudest external commentary was adversarial (David Liu's efficiency critique) rather than corroborating — the opposite of the validation an editing platform needs.

Lens 7 · Cap Table & Secondary Marks (+private) + Mechanism Comps (+clinical)

Syndicate quality (+private): genuinely tier-1 — a16z Bio+Health, ARCH Venture Partners, GV (Google Ventures), Polaris, Longwood, plus strategics Bruker and FUJIFILM and real-estate/CVC Alexandria. Notably no crossover fund (Fidelity / T. Rowe / Coatue) IPO-proximity tell — consistent with a very-early platform, not an IPO-track company. Secondary marks: not disclosed; given the wind-down, any secondary would price at distressed/near-zero. n/a — private, not disclosed for a hard mark.

Mechanism comps (+clinical — by target/technology, NOT by P/E). Multiples are `` or n/a:

No multiples fabricated — pull live from a market data source before any valuation use.

Lens 8 · Value-Inflection / Catalyst Events (adapted from Stock-Price Catalysts — no stock, so this maps the events that moved the company's fortunes)

Pattern: the market that mattered here (private VC) reacted to capital-efficiency and clinical-proximity, not raw technical wow. Tome had the wow and neither of the other two.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO — Rahul Kakkar, MD. Physician + serial biotech operator. Track record before Tome is genuinely strong: led Pandion Therapeutics to a $1.85–2.0B acquisition by Merck (2021). That credential is what unlocked the $213M raise. On his Tome watch, capital allocation was poor (see Lens 10 / the Replace deal), and the company failed within a year. He exited to run Quotient Therapeutics — i.e., the operator moved on; he is not going down with the ship. Archetype: professional biotech-builder/dealmaker, not a bench founder.
• Scientific founders — Omar Abudayyeh, PhD & Jonathan Gootenberg, PhD. The crown jewels. Trained under Feng Zhang (Broad/MIT), co-invented PASTE, and are prolific (co-authored ~10 papers, co-founded Sherlock Biosciences [acquired], Proof Diagnostics [acquired], Terrain Biosciences). They run the AbuGoot Lab with Harvard faculty appointments and continue publishing programmable-biology tools. This is the most important "asset" that survived Tome — the human capital and the ongoing academic pipeline, not the corporate shell.
• CSO — John Finn (early Intellia; led its CRISPR clinical translation). Emerged from the collapse with credit for the "salvage mode" preprint push — a class act that preserved the science.
• CTO — Matt Barrows (led Moderna COVID manufacturing scale-up).
• Skin in the game / insider ownership: private, undisclosed — n/a — not disclosed. No insider-transactions.csv.
• Red flags: (1) the Replace acquisition — buying a second unvalidated platform for $65M+ upfront within weeks of launch, before de-risking the core, in a deteriorating market; (2) overstaffing to ~130–150 FTE pre-clinically while burning >$100M/yr; (3) narrative that leaned on "revolutionary" language while the independent scientific commentary was skeptical.

Lens 10 · Forensic Red Flags

No audited financials exist (private) — so this is a capital-and-governance forensic, not an accounting one, plus the required regulatory sub-section.

• Cash-flow vs. burn: the defining red flag is duration — $213M raised, exhausted in <12 months. Even absent a P&L, the arithmetic is damning: **~$100M+ annualized gross burn ** with zero revenue and no near-term clinical catalyst to bridge to the next raise.
• Capital allocation (the core forensic finding): the Replace Therapeutics acquisition (Jan 2024) consumed scarce runway on a second, still-unvalidated technology (L-PGI) before the first (I-PGI) had reached the clinic — widely cited post-hoc as "premature and poorly vetted" and a primary cause of the collapse.
• Platform-over-asset risk: classic pre-clinical-platform failure mode — spread across PKU + autoimmune + two edit technologies rather than driving one asset to IND. The 2024 market "heavily prefers clinical-stage companies with well-defined niches"; Tome was the opposite.
• IP contingency: unresolved question of whether PASTE deployment requires a prime-editing license (Broad/Prime Medicine estate) — a latent liability, not a settled freedom-to-operate.
• Going-concern: by Aug 2024, self-evidently a going-concern failure (out of cash, winding down).

Regulatory findings (required sub-section):

• SEC (EDGAR LR + AAER): None — Tome has no CIK, is private, and files nothing with the SEC. No EDGAR enforcement search is possible.
• Non-SEC (FTC/DOJ/FDA/CFPB) web search "Tome Biosciences" (FTC OR DOJ OR FDA OR settlement OR fine OR penalty) enforcement: no material enforcement, consent decree, fine, or penalty found. The only legal/quasi-legal filing of note is the Massachusetts WARN Act notice (a mandatory mass-layoff disclosure — not an enforcement action).
• 10-K Item 3 (Legal Proceedings): n/a — no 10-K exists (private, no CIK). Not fabricated.
• Net: No material regulatory or legal enforcement findings — verified via SEC EDGAR EFTS (LR, AAER, nil — no CIK), web search (nil enforcement), and the absence of any SEC filing, as of 2026-07-06. The IP-license overhang (prime editing) is a commercial risk, not a regulatory finding.

---

Phase D — Project & stress-test

Lens 11 · IPO-Readiness / Path-to-Tradeable (+private) + rNPV/runway (+clinical)

IPO readiness: 0 / 5 — there is no path to tradeable. The company wound down; there is no S-1 pathway, no ongoing operations, no cap table to take public. (private-watch.json carries no Tome entry — it tracks a different AI/robotics/fusion cohort — so there is no readiness score to update, and the run brief forbids editing the watch/index anyway.) n/a — entity defunct.

rNPV / runway-to-catalyst (the +clinical question that actually mattered): the decisive input was never rNPV of the PKU asset — it was runway. Runway did not reach the value-inflection catalyst (an IND / first-in-human), because the Series C failed. A rough illustrative rNPV would be moot: PoS collapses to ~0 once the developing entity ceases to exist, regardless of the underlying biology. Any residual value now lives in out-licensed IP / the salvaged preprints / the founders' academic lab, not in a corporate NPV. ``.

No Brier forecast logged (per --watchlist rules: skip forecast.ts create; and there is no live binary readout to score — the company is defunct). The only forward-looking, scoreable proposition worth noting for the shelf: "PASTE/PGI reaches a first-in-human trial under any successor entity or licensee by YE2027" — base rate LOW given the asset dispersal and PASSIGE's efficiency lead. Not logged.

Lens 12 · Bull vs Bear (adversarial)

Bull case (what a16z and the syndicate believed — and it isn't crazy): PGI is the logical endgame of genome editing — mutation-agnostic, whole-gene, break-free insertion collapses the "one-drug-per-mutation" economics that make base/prime editing commercially painful for rare monogenic diseases. The >10% NHP liver insertion shows the biology can reach curative thresholds. The founders are generationally strong (Zhang lineage, multiple prior exits). In a healthy 2021-style capital market, this raises a Series C, IND's the PKU program, and becomes a real company. The technology thesis was directionally right; the company was born into the wrong market.

Bear case (2–3 permanent-impairment risks — all of which fired):

1. Efficiency gap vs. the inventor of the underlying method. David Liu's PASSIGE (eeBxb1, ~23%) reportedly beats PASTE on integration efficiency, and Liu publicly disputes the value of Tome's fused architecture. A large-cargo tool that a rival matches on capability and beats on efficiency has no durable technical moat.
2. Capital-allocation self-harm into a closing window. The $65M+ Replace acquisition shortened the runway exactly when the sector's funding was drying up. Preclinical platforms with diffuse pipelines were precisely what 2024 capital fled.
3. Sector re-rating. Gene editing entered a multi-year winter (Editas −65%, Intellia −27%, Beam/CRISPR downsizing) — even clinical leaders got cut; a preclinical, cash-hungry, unproven-efficiency platform had no chance to raise.

Pre-mortem (written as if 18 months out — except it already happened): "It's late 2024. The thesis broke because the company spent like the 2021 market would return, bought a second platform before proving the first, and hit a funding winter with no clinical catalyst and a competitor claiming higher efficiency. The Series C never closed. The science was salvaged into preprints; the company was salvaged into a domain-for-sale."

Are the multiples too high? n/a — no public equity. The private mark went from launch-high to salvage in <12 months.

Contrarian view (what the market may still be refusing to see): the PGI concept is not dead — only this vehicle is. The winning form may be Liu's PASSIGE (via Prime Medicine), Tessera's gene writing, or a Metagenomi integrase, and/or the AbuGoot lab's next-generation tools re-emerging in a fresh, better-capitalized, more focused startup once the editing winter thaws. The asset to track is the idea and the people, not Tome the corpse.

Lens 13 · Devil's Advocate (short-seller)

(If Tome were somehow public, here is the dismantling — and it doubles as the epitaph.)

• What structurally breaks the model? It already did: a pre-revenue platform that cannot self-fund and cannot out-raise its burn dies when VC sentiment turns. Zero revenue = zero shock absorber.
• Where is "revenue" (here, value) concentrated? In one contested technology and two pre-clinical programs, atop one university license with a prime-editing IP overhang. Every leg is single-threaded.
• Why is the moat weaker than bulls think? Because the inventor of the enabling method (Liu) competes against you and claims your architecture confers no benefit and lower efficiency. That is close to a fatal external verdict for a tools/platform company.
• Most dangerous competitor bulls underestimated: Prime Medicine / David Liu's PASSIGE — same large-insertion capability, higher claimed efficiency, cleaner IP root, public-company balance sheet. Also Tessera (better-funded private).
• Worst capital-allocation move: the Replace acquisition — textbook "di-worsification" of a scarce balance sheet.
• What assumptions had to hold and didn't: (a) friendly capital markets through ~2026; (b) PASTE efficiency ≥ rivals; (c) a near-term clinical catalyst. All three failed.
• Valuation if growth disappoints 20–30%? Irrelevant — it disappeared 100%.
• Single scenario that permanently impairs the business: "Series C fails in a gene-editing winter." Plausibility at the time: high. It happened.

Lens 14 · Management Questions (ordered by information value — reframed as the questions this failure poses, for the founders/CEO and for any investor eyeing a successor entity or the surviving IP)

1. Why acquire Replace Therapeutics ($65M+) before I-PGI reached IND — what runway assumption justified spending scarce cash on a second unvalidated platform? (The single highest-information question — it isolates the decision most cited as fatal.)
2. On head-to-head, standardized assays, what is PASTE's integration efficiency vs. PASSIGE (eeBxb1) at matched loci — and does the fused architecture ever win?
3. What was the actual gross monthly burn and the runway at the time of the Series C attempt?
4. How many, and which type of, investors were in the failed Series C — was it price, data, or sector-wide risk-off that killed it?
5. Did any of the "at least three" interested acquirers complete a deal for the pipeline or platform, and on what terms? Where did the PKU and CAR-iNK assets ultimately go?
6. What is the freedom-to-operate position on prime editing — is a Broad/Prime Medicine license required for clinical PASTE, and was that ever secured?
7. Where do the rights to the MIT PASTE license and the Replace/L-PGI IP now sit?
8. Would a leaner, single-asset (PKU-only) company have survived — why was the pipeline kept broad?
9. What did the >10% NHP liver insertion data actually show on off-target integration / genotoxicity, not just on-target efficiency?
10. Are the seven salvage preprints the full disclosure of the platform's capabilities, or was key know-how retained/lost with the team?
11. What delivery modality (LNP vs. viral) was the PKU program committed to, and how far was manufacturing from GMP?
12. Did the strategic hires (Moderna-manufacturing CTO, Intellia CSO) reflect a clinical timeline that the balance sheet could never fund?
13. Would the founders build a successor PGI company — and what would they do differently on capitalization and focus?
14. What governance/board dynamics allowed a <12-month cash exhaustion to occur without an earlier pivot to a lean-and-survive posture?
15. Is there any scenario in which PGI/large-cargo insertion becomes a real therapeutic class this decade, and which vehicle (PASSIGE, Tessera, Metagenomi, a new AbuGoot startup) is most likely to get there first?

---